全文获取类型
收费全文 | 97421篇 |
免费 | 9248篇 |
国内免费 | 6384篇 |
专业分类
耳鼻咽喉 | 907篇 |
儿科学 | 1158篇 |
妇产科学 | 944篇 |
基础医学 | 10886篇 |
口腔科学 | 1895篇 |
临床医学 | 12497篇 |
内科学 | 13531篇 |
皮肤病学 | 1191篇 |
神经病学 | 4260篇 |
特种医学 | 3418篇 |
外国民族医学 | 48篇 |
外科学 | 9311篇 |
综合类 | 17798篇 |
现状与发展 | 29篇 |
一般理论 | 16篇 |
预防医学 | 8060篇 |
眼科学 | 2330篇 |
药学 | 10796篇 |
99篇 | |
中国医学 | 6125篇 |
肿瘤学 | 7754篇 |
出版年
2024年 | 373篇 |
2023年 | 1417篇 |
2022年 | 3610篇 |
2021年 | 4870篇 |
2020年 | 3656篇 |
2019年 | 3008篇 |
2018年 | 3217篇 |
2017年 | 3026篇 |
2016年 | 2834篇 |
2015年 | 4595篇 |
2014年 | 5551篇 |
2013年 | 5370篇 |
2012年 | 7621篇 |
2011年 | 8327篇 |
2010年 | 5900篇 |
2009年 | 4766篇 |
2008年 | 5643篇 |
2007年 | 5586篇 |
2006年 | 5310篇 |
2005年 | 4892篇 |
2004年 | 3681篇 |
2003年 | 3478篇 |
2002年 | 2881篇 |
2001年 | 2326篇 |
2000年 | 1995篇 |
1999年 | 1788篇 |
1998年 | 1152篇 |
1997年 | 1066篇 |
1996年 | 789篇 |
1995年 | 799篇 |
1994年 | 670篇 |
1993年 | 396篇 |
1992年 | 453篇 |
1991年 | 402篇 |
1990年 | 333篇 |
1989年 | 286篇 |
1988年 | 229篇 |
1987年 | 221篇 |
1986年 | 150篇 |
1985年 | 124篇 |
1984年 | 73篇 |
1983年 | 44篇 |
1982年 | 24篇 |
1981年 | 31篇 |
1980年 | 11篇 |
1979年 | 43篇 |
1977年 | 4篇 |
1976年 | 5篇 |
1970年 | 4篇 |
1969年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
12.
L.‐Q. Zheng X.‐C. Han Y. Huang H.‐W. Li X.‐D. Niu J. Li 《Clinical and experimental dermatology》2015,40(3):293-297
Porocarcinoma is an unusual, locally aggressive and potentially fatal neoplasm. Several cutaneous malignancies have been described in association with porocarcinoma, including squamous cell carcinoma, basal cell carcinoma and tricholemmal carcinoma. Previous reports have indicated that the occurrence of malignant tumours in combination with porocarcinoma is extremely rare, in particular with regard to Bowen disease (BD). We report an uncommon case of porocarcinoma occurring synchronously in a single BD lesion in a 63‐year‐old woman with multiple BD lesions. The clinical and histological findings confirmed this diagnosis. 相似文献
13.
JeongYun Choi Haeseung Lee EunJi Kwon HyeonJoon Kong OkSeon Kwon HyukJin Cha 《Molecular oncology》2021,15(2):679
The acquisition of chemoresistance remains a major cause of cancer mortality due to the limited accessibility of targeted or immune therapies. However, given that severe alterations of molecular features during epithelial‐to‐mesenchymal transition (EMT) lead to acquired chemoresistance, emerging studies have focused on identifying targetable drivers associated with acquired chemoresistance. Particularly, AXL, a key receptor tyrosine kinase that confers resistance against targets and chemotherapeutics, is highly expressed in mesenchymal cancer cells. However, the underlying mechanism of AXL induction in mesenchymal cancer cells is poorly understood. Our study revealed that the YAP signature, which was highly enriched in mesenchymal‐type lung cancer, was closely correlated to AXL expression in 181 lung cancer cell lines. Moreover, using isogenic lung cancer cell pairs, we also found that doxorubicin treatment induced YAP nuclear translocation in mesenchymal‐type lung cancer cells to induce AXL expression. Additionally, the concurrent activation of TGFβ signaling coordinated YAP‐dependent AXL expression through SMAD4. These data suggest that crosstalk between YAP and the TGFβ/SMAD axis upon treatment with chemotherapeutics might be a promising target to improve chemosensitivity in mesenchymal‐type lung cancer.
Abbreviations
- AUC
- area under the curve
- AXL
- AXL receptor tyrosine kinase
- BCL2
- B‐cell lymphoma 2
- CTD2
- cancer target discovery and development
- CTGF
- connective tissue growth factor
- DEG
- differentially expressed genes
- DOXO
- doxorubicin
- EMT
- epithelial–mesenchymal transition
- Eto
- etoposide
- FDA
- Food and Drug Administration
- ITGB3
- integrin beta‐3
- MAPK
- mitogen‐activated protein kinase
- MMP2
- matrix metalloproteinase‐2
- MMP9
- matrix metalloproteinase‐9
- mRNA
- messenger RNA
- NF‐κB
- nuclear factor kappa‐light‐chain‐enhancer of activated B cells
- SBE
- SMAD binding element
- SERPINE1
- serpin family E member 1
- siRNA
- small interfering RNA
- ssGSEA
- single‐sample gene set enrichment analysis
- TCGA
- The Cancer Genome Atlas
- TGFβ
- transforming growth factor beta
- YAP
- Yes‐associated protein
- YAP8SA
- mutants of inhibitory phosphorylation site at eight serine to Alanine of YAP
- ZEB1
- zinc finger E‐box binding homeobox 1
- ZEB2
- zinc finger E‐box‐binding homeobox 2
14.
15.
目的本研究立足于项目组前期研究的成果上,积极探索吉林辽宁两省目标设置水平的差异,并进一步探究受目标设置影响下的工作落实结果情况,探讨产生差异的原因。
方法以系统穷尽的方式收集吉林辽宁两省2000至2017年有关目标与工作落实情况的指标,利用Spearman相关和线性回归分析吉林辽宁两省目标设置对于突发应急工作落实情况的影响。
结果吉林辽宁两省突发应急领域的目标设置水平与工作落实情况总体均呈现上升趋势,截至2017年,吉林目标设置水平与工作落实情况分别为46%与60%,辽宁为60%与53.3%,且目标设置水平与工作落实呈正相关。
结论有公众需要为依据且定量可考的目标设置对于工作落实、推进、完善具有积极的正反馈作用,建立科学量化的突发应急目标设置评价体系是适宜可行的。 相似文献
16.
17.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
18.
19.
20.